Product Description
Stiripentol is used along with clobazam (Onfi®) to control seizures in adults and children 2 years of age and older who have Dravet syndrome (a disorder that begins in early childhood and causes seizures and later may lead to developmental delays and changes in eating, balance, and walking). Stiripentol is in a class of medications called anticonvulsants. It works by decreasing abnormal excitement activity in the brain. (Sourced from: https://medlineplus.gov/druginfo/meds/a618069.html)
Mechanisms of Action: GABA Agonist,Cytochrome P450 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Canada | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Japan | Latvia | Lithuania | Netherlands | New Zealand | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Biocodex
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Bulgaria, France, Italy
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Hyperoxaluria, Primary
Phase 1: Kidney Failure, Chronic